Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).

Saito S, Alkhatib A, Kolls JK, Kondoh Y, Lasky JA.

J Thorac Dis. 2019 Sep;11(Suppl 14):S1740-S1754. doi: 10.21037/jtd.2019.04.62. Review.

2.

Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes.

Casanova N, Zhou T, Gonzalez-Garay ML, Rosas IO, Goldberg HJ, Ryter SW, Collard HR, El-Chemaly S, Flaherty KR, Hunninghake GM, Lasky JA, Lederer DJ, Machado RF, Martinez FJ, Noth I, Raghu G, Choi AMK, Garcia JGN.

Sci Rep. 2019 Oct 15;9(1):14802. doi: 10.1038/s41598-019-50585-3.

3.

Attenuation of Allergen-, IL-13-, and TGF-α-induced Lung Fibrosis after the Treatment of rIL-15 in Mice.

Upparahalli Venkateshaiah S, Niranjan R, Manohar M, Verma AK, Kandikattu HK, Lasky JA, Mishra A.

Am J Respir Cell Mol Biol. 2019 Jul;61(1):97-109. doi: 10.1165/rcmb.2018-0254OC.

PMID:
30702923
4.

Radial Endobronchial Ultrasound-guided Transbronchial Cryobiopsy.

Abdelghani R, Thakore S, Kaphle U, Lasky JA, Kheir F.

J Bronchology Interv Pulmonol. 2019 Oct;26(4):245-249. doi: 10.1097/LBR.0000000000000566.

PMID:
30676396
5.

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.

Korfei M, Stelmaszek D, MacKenzie B, Skwarna S, Chillappagari S, Bach AC, Ruppert C, Saito S, Mahavadi P, Klepetko W, Fink L, Seeger W, Lasky JA, Pullamsetti SS, Krämer OH, Guenther A.

PLoS One. 2018 Nov 27;13(11):e0207915. doi: 10.1371/journal.pone.0207915. eCollection 2018.

6.

HDAC8 inhibition ameliorates pulmonary fibrosis.

Saito S, Zhuang Y, Suzuki T, Ota Y, Bateman ME, Alkhatib AL, Morris GF, Lasky JA.

Am J Physiol Lung Cell Mol Physiol. 2019 Jan 1;316(1):L175-L186. doi: 10.1152/ajplung.00551.2017. Epub 2018 Oct 25.

PMID:
30358439
7.

Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective.

Saito S, Lasky JA, Hagiwara K, Kondoh Y.

Respir Investig. 2018 Sep;56(5):375-383. doi: 10.1016/j.resinv.2018.06.002. Epub 2018 Jul 27. Review.

PMID:
30061050
8.

A 56-Year-Old-Man With Common Variable Immunodeficiency and Worsening Dyspnea.

Limsuwat C, Daroca PJ, Lasky JA.

Chest. 2018 Jul;154(1):e27-e30. doi: 10.1016/j.chest.2017.11.034.

PMID:
30044751
9.

A critical role for IL-18 in transformation and maturation of naive eosinophils to pathogenic eosinophils.

Venkateshaiah SU, Mishra A, Manohar M, Verma AK, Rajavelu P, Niranjan R, Wild LG, Parada NA, Blecker U, Lasky JA, Mishra A.

J Allergy Clin Immunol. 2018 Jul;142(1):301-305. doi: 10.1016/j.jaci.2018.02.011. Epub 2018 Mar 2. No abstract available.

10.

A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis.

Rosas IO, Goldberg HJ, Collard HR, El-Chemaly S, Flaherty K, Hunninghake GM, Lasky JA, Lederer DJ, Machado R, Martinez FJ, Maurer R, Teller D, Noth I, Peters E, Raghu G, Garcia JGN, Choi AMK.

Chest. 2018 Jan;153(1):94-104. doi: 10.1016/j.chest.2017.09.052. Epub 2017 Oct 31.

11.

Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.

Saito S, Zhuang Y, Shan B, Danchuk S, Luo F, Korfei M, Guenther A, Lasky JA.

PLoS One. 2017 Oct 18;12(10):e0186615. doi: 10.1371/journal.pone.0186615. eCollection 2017.

12.

The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.

Sanchez CG, Molinski SV, Gongora R, Sosulski M, Fuselier T, MacKinnon SS, Mondal D, Lasky JA.

Arthritis Rheumatol. 2018 Jan;70(1):115-126. doi: 10.1002/art.40326. Epub 2017 Dec 8.

13.

Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells.

Yin Q, Sides M, Parsons CH, Flemington EK, Lasky JA.

Virol J. 2017 Jun 21;14(1):121. doi: 10.1186/s12985-017-0784-7.

14.

Regulatory effects of IL-15 on allergen-induced airway obstruction.

Venkateshaiah SU, Zhu X, Rajavelu P, Niranjan R, Manohar M, Verma AK, Lasky JA, Mishra A.

J Allergy Clin Immunol. 2018 Mar;141(3):906-917.e6. doi: 10.1016/j.jaci.2017.05.025. Epub 2017 Jun 9.

15.

TGF-β1 stimulates HDAC4 nucleus-to-cytoplasm translocation and NADPH oxidase 4-derived reactive oxygen species in normal human lung fibroblasts.

Guo W, Saito S, Sanchez CG, Zhuang Y, Gongora Rosero RE, Shan B, Luo F, Lasky JA.

Am J Physiol Lung Cell Mol Physiol. 2017 Jun 1;312(6):L936-L944. doi: 10.1152/ajplung.00256.2016. Epub 2017 Mar 23.

16.

Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells.

Liu YZ, Zhang L, Roy-Engel AM, Saito S, Lasky JA, Wang G, Wang H.

Gene. 2017 Feb 20;602:16-23. doi: 10.1016/j.gene.2016.11.028. Epub 2016 Nov 16.

17.

Sirtuin 3 Deregulation Promotes Pulmonary Fibrosis.

Sosulski ML, Gongora R, Feghali-Bostwick C, Lasky JA, Sanchez CG.

J Gerontol A Biol Sci Med Sci. 2017 May 1;72(5):595-602. doi: 10.1093/gerona/glw151.

18.

Methylation status and AP1 elements are involved in EBV-mediated miR-155 expression in EBV positive lymphoma cells.

Yin Q, Wang X, Roberts C, Flemington EK, Lasky JA.

Virology. 2016 Jul;494:158-67. doi: 10.1016/j.virol.2016.04.005. Epub 2016 Apr 26.

19.

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.

Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, Pelling K, Quaresma M, Lasky JA.

Respir Res. 2015 Sep 24;16:116. doi: 10.1186/s12931-015-0276-5.

20.

Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation.

Esposito DB, Lanes S, Donneyong M, Holick CN, Lasky JA, Lederer D, Nathan SD, O'Quinn S, Parker J, Tran TN.

Am J Respir Crit Care Med. 2015 Nov 15;192(10):1200-7. doi: 10.1164/rccm.201504-0818OC.

PMID:
26241562
21.

Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Lammi MR, Baughman RP, Birring SS, Russell AM, Ryu JH, Scholand M, Distler O, LeSage D, Sarver C, Antoniou K, Highland KB, Kowal-Bielecka O, Lasky JA, Wells AU, Saketkoo LA.

Curr Respir Med Rev. 2015;11(2):163-174.

22.

Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo.

Luo F, Zhuang Y, Sides MD, Sanchez CG, Shan B, White ES, Lasky JA.

Respir Res. 2014 Apr 24;15:51. doi: 10.1186/1465-9921-15-51.

23.

Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.

Pankey EA, Thammasiboon S, Lasker GF, Baber S, Lasky JA, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2013 Nov 1;305(9):H1288-96. doi: 10.1152/ajpheart.00329.2013. Epub 2013 Aug 30.

24.

Detecting splicing variants in idiopathic pulmonary fibrosis from non-differentially expressed genes.

Deng N, Sanchez CG, Lasky JA, Zhu D.

PLoS One. 2013 Jul 2;8(7):e68352. doi: 10.1371/journal.pone.0068352. Print 2013.

25.

Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma.

Sides MD, Sosulski ML, Luo F, Lin Z, Flemington EK, Lasky JA.

Virol J. 2013 May 16;10:152. doi: 10.1186/1743-422X-10-152.

26.
27.

Overexpression of Sulf2 in idiopathic pulmonary fibrosis.

Yue X, Lu J, Auduong L, Sides MD, Lasky JA.

Glycobiology. 2013 Jun;23(6):709-19. doi: 10.1093/glycob/cwt010. Epub 2013 Feb 14.

28.

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ.

N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20.

29.

Epstein - Barr virus Latent Membrane Protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies.

Sides MD, Block GJ, Chadwick RW, Shan B, Flemington EK, Lasky JA.

Virol J. 2011 Oct 5;8:461. doi: 10.1186/1743-422X-8-461.

30.

Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.

Sides MD, Block GJ, Shan B, Esteves KC, Lin Z, Flemington EK, Lasky JA.

Virology. 2011 Jul 20;416(1-2):86-97. doi: 10.1016/j.virol.2011.04.005. Epub 2011 May 24.

31.

Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6.

Danchuk S, Ylostalo JH, Hossain F, Sorge R, Ramsey A, Bonvillain RW, Lasky JA, Bunnell BA, Welsh DA, Prockop DJ, Sullivan DE.

Stem Cell Res Ther. 2011 May 13;2(3):27. doi: 10.1186/scrt68.

32.

Pharmacological inhibition of HDAC6 attenuates endothelial barrier dysfunction induced by thrombin.

Saito S, Lasky JA, Guo W, Nguyen H, Mai A, Danchuk S, Sullivan DE, Shan B.

Biochem Biophys Res Commun. 2011 May 20;408(4):630-4. doi: 10.1016/j.bbrc.2011.04.075. Epub 2011 Apr 21.

33.

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis.

Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.

34.

Modulation of lung inflammation by the Epstein-Barr virus protein Zta.

Guenther JF, Cameron JE, Nguyen HT, Wang Y, Sullivan DE, Shan B, Lasky JA, Flemington EK, Morris GF.

Am J Physiol Lung Cell Mol Physiol. 2010 Dec;299(6):L771-84. doi: 10.1152/ajplung.00408.2009. Epub 2010 Sep 3.

35.

The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--β1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells.

Sides MD, Klingsberg RC, Shan B, Gordon KA, Nguyen HT, Lin Z, Takahashi T, Flemington EK, Lasky JA.

Am J Respir Cell Mol Biol. 2011 Jun;44(6):852-62. doi: 10.1165/rcmb.2009-0232OC. Epub 2010 Aug 6.

36.

Thy-1 attenuates TNF-alpha-activated gene expression in mouse embryonic fibroblasts via Src family kinase.

Shan B, Hagood JS, Zhuo Y, Nguyen HT, MacEwen M, Morris GF, Lasky JA.

PLoS One. 2010 Jul 19;5(7):e11662. doi: 10.1371/journal.pone.0011662.

37.

TGF-β: Titan of Lung Fibrogenesis.

Yue X, Shan B, Lasky JA.

Curr Enzym Inhib. 2010 Jul 1;6(2). doi: 10.2174/10067.

38.

Current clinical trials for the treatment of idiopathic pulmonary fibrosis.

Klingsberg RC, Mutsaers SE, Lasky JA.

Respirology. 2010 Jan;15(1):19-31. doi: 10.1111/j.1440-1843.2009.01672.x. Review.

PMID:
20199632
39.

Requirement of a novel splicing variant of human histone deacetylase 6 for TGF-beta1-mediated gene activation.

Zhuang Y, Nguyen HT, Lasky JA, Cao S, Li C, Hu J, Guo X, Burow ME, Shan B.

Biochem Biophys Res Commun. 2010 Feb 19;392(4):608-13. doi: 10.1016/j.bbrc.2010.01.091. Epub 2010 Jan 25.

40.

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.

Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators.

Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.

PMID:
20007927
41.

Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition.

Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA.

Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L864-70. doi: 10.1152/ajplung.00128.2009. Epub 2009 Aug 21.

42.

Characterization of erectile function in monocrotaline-treated pulmonary hypertensive rats.

Gur S, Kadowitz PJ, Thammasitboon S, Lasky JA, Hellstrom WJ.

J Androl. 2009 Sep-Oct;30(5):495-504. doi: 10.2164/jandrol.108.006700. Epub 2009 Feb 5.

43.

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, Fatenejad S.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):948-55. doi: 10.1164/rccm.200709-1446OC. Epub 2008 Jul 31.

PMID:
18669816
44.

Transforming growth factor-beta1 induces heparan sulfate 6-O-endosulfatase 1 expression in vitro and in vivo.

Yue X, Li X, Nguyen HT, Chin DR, Sullivan DE, Lasky JA.

J Biol Chem. 2008 Jul 18;283(29):20397-407. doi: 10.1074/jbc.M802850200. Epub 2008 May 23.

45.

Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition.

Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, Tao H, Palmer ML, Holder KN, Lasky JA.

J Biol Chem. 2008 Jul 25;283(30):21065-73. doi: 10.1074/jbc.M802786200. Epub 2008 May 21.

46.

Bone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertension.

Spees JL, Whitney MJ, Sullivan DE, Lasky JA, Laboy M, Ylostalo J, Prockop DJ.

FASEB J. 2008 Apr;22(4):1226-36. Epub 2007 Nov 21.

PMID:
18032636
47.

Kaposi's sarcoma associated herpesvirus G-protein coupled receptor activation of cyclooxygenase-2 in vascular endothelial cells.

Shelby BD, LaMarca HL, McFerrin HE, Nelson AB, Lasky JA, Sun G, Myatt L, Offermann MK, Morris CA, Sullivan DE.

Virol J. 2007 Sep 14;4:87.

48.

Acute exacerbations of idiopathic pulmonary fibrosis.

Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators.

Am J Respir Crit Care Med. 2007 Oct 1;176(7):636-43. Epub 2007 Jun 21. Review.

49.

Engraftment of bone marrow progenitor cells in a rat model of asbestos-induced pulmonary fibrosis.

Spees JL, Pociask DA, Sullivan DE, Whitney MJ, Lasky JA, Prockop DJ, Brody AR.

Am J Respir Crit Care Med. 2007 Aug 15;176(4):385-94. Epub 2007 May 11.

50.

Intravenous injection of methylprednisolone reduces the incidence of postextubation stridor in intensive care unit patients.

Li J, Simeone F, Freyder L, Lasky JA.

Crit Care Med. 2007 May;35(5):1443; author reply 1443. No abstract available.

PMID:
17446756

Supplemental Content

Loading ...
Support Center